Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Letetresgene autoleucel - US WorldMeds

Next Previous
Drug Profile

Letetresgene autoleucel - US WorldMeds

Alternative Names: GSK 794; GSK-3377794; lete-cel; NY-ESO SPEAR T-cell therapy - GlaxoSmithKline; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1 TCR T; NY-ESO-1-specific T-cells - Adaptimmune; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1c259T; NY-ESO-1c259-antigen-specific-T-cell-receptor-gene-therapy; NY-ESO-1c259-modified-T-cells; NY-ESO-1c259-TCR-transduced-lymphocytes; NY-ESO-1c259-TCR-transduced-T-cells; NY-ESO-c259T

Latest Information Update: 09 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; GlaxoSmithKline; GSK; Merck & Co; US WorldMeds
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastrointestinal cancer; Liposarcoma; Malignant melanoma; Multiple myeloma; Myxoid liposarcoma; Non-small cell lung cancer; Ovarian cancer; Synovial sarcoma
  • No development reported Liver cancer; Prostate cancer

Most Recent Events

  • 09 Sep 2026 US WorldMeds completes phase-II clinical trials in Synovial sarcoma (Metastatic disease, Late-stage disease, Inoperable/Unresectable, In adults, In adolescents, In children) in USA, Canada, Canada, Italy, France, Netherlands, Spain, United Kingdom (IV) (NCT06703346)
  • 24 Jul 2026 US WorldMeds completes phase II clinical trials in Myxoid liposarcoma (In adolescents, In children, In adults, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA, Canada, France, Italy, Netherlands, Spain, United Kingdom (IV) (NCT06703346)
  • 02 Jun 2026 Efficacy, adverse events and pharmacokinetics data from a phase I/II pilot trial and phase II IGNYTE-ESO trial in Synovial sarcoma trial presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top